公开(公告)号：EP2428216A9

公开(公告)日：2012-04-25

申请号：EP11184922.0

申请日：2005-05-20

申请人： ZymoGenetics, Inc.

发明人： Hughes, Steven D. ,  Kindsvogel, Wayne R. ,  Holly, Richard D. ,  Clegg, Christopher H. ,  Foster, Donald C. ,  Johnson, Rebecca A. ,  Heipel, Mark D. ,  Sivakumar, Pallavur V.

IPC分类号： A61K38/20 ,  A61K39/395 ,  C07K16/28 ,  C07K16/32

CPC分类号： C07K16/32 ,  A61K38/20 ,  A61K39/395 ,  A61K39/39558 ,  C07K16/2818 ,  C07K16/2896 ,  C07K2317/732 ,  A61K2300/00

摘要： There is provided a monoclonal antibody that binds to binds to cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), programmed death-1 (PD-1), B and T lymphocyte attenuator (BTLA), IL-10, TGFβ, or CD25, and an IL-21 polypeptide or fragment of an IL-21 polypeptide as shown in SEQ ID NO:2 from amino acid residue 30 to residue 162, for use in treating cancer in a subject.

摘要翻译： 提供了结合细胞毒性T淋巴细胞相关抗原4（CTLA-4），程序性死亡-1（PD-1），B和T淋巴细胞衰减剂（BTLA），IL-10，TGFβ或 CD25和IL-21多肽或IL-21多肽的片段，如SEQ ID NO：2所示，从氨基酸残基30至残基162，用于治疗受试者的癌症。

公开(公告)号：EP1436003B3

公开(公告)日：2012-03-14

申请号：EP02734478.7

申请日：2002-05-20

申请人： ZymoGenetics, Inc.

发明人： RIXON, Mark, W. ,  GROSS, Jane, A.

IPC分类号： A61K39/395 ,  C07K16/00 ,  C07K14/705

CPC分类号： C07K16/241 ,  A61K38/00 ,  A61K39/3955 ,  A61K45/06 ,  C07K14/70578 ,  C07K2319/00 ,  C07K2319/30

摘要： Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.

公开(公告)号：EP2392597A3

公开(公告)日：2012-03-07

申请号：EP11168730.7

申请日：2008-04-28

申请人： ZymoGenetics, Inc.

发明人： Lewis, Katherine E. ,  Presnell, Scott R. ,  Levin, Steven D.

IPC分类号： C07K16/24 ,  A61K39/395 ,  C07K16/46 ,  A61P37/06

CPC分类号： C07K16/244 ,  A61K2039/507 ,  C07K2317/31 ,  C07K2317/56

摘要： There is provided an antagonist of IL-23 and of IL-17A or IL-17F comprising: (i) an antibody or antibody fragment that binds the p19 subunit of IL-23 as shown in SEQ ID NO: 4; and (ii) an antibody or antibody fragment that binds IL-17A as shown in SEQ ID NO: 2 or that binds IL-17F as shown in SEQ ID NO: 6; wherein the antibody or antibody fragment that binds IL-17A or IL-17F comprises a HCDR1 amino acid sequence, a HCDR2 amino acid sequence, and a HCDR3 amino acid sequence of the variable heavy region selected from the group consisting of the variable heavy region of the hybridoma of ATCC Patent Deposit Designation PTA-7988; and wherein the variable light region comprises a LCDR1 amino acid sequence, a LCDR2 amino acid sequence, and a LCDR3 amino acid sequence of the variable light region of the hybridoma of ATCC Patent Deposit Designation PTA-7988.

公开(公告)号：EP2116259B1

公开(公告)日：2012-01-25

申请号：EP09168970.3

申请日：2002-05-20

申请人： ZymoGenetics, Inc.

发明人： Rixon, Mark W ,  Gross, Jane A

IPC分类号： A61K39/395 ,  C07K16/00 ,  C07K14/705

CPC分类号： C07K16/241 ,  A61K38/00 ,  A61K39/3955 ,  A61K45/06 ,  C07K14/70578 ,  C07K2319/00 ,  C07K2319/30

公开(公告)号：EP2377549A1

公开(公告)日：2011-10-19

申请号：EP11168848.7

申请日：2003-06-06

申请人： ZymoGenetics, Inc.

发明人： Nelson, Andrew J. ,  Hughes, Steven D. ,  Holly, Richard D. ,  Kindsvogel, Wayne, R.

IPC分类号： A61K39/00 ,  A61K38/20 ,  A61P31/12 ,  C07K14/54

CPC分类号： C07K14/54 ,  A61K38/193 ,  A61K38/20 ,  A61K38/2013 ,  A61K38/2026 ,  A61K38/2086 ,  A61K45/06 ,  C07K16/2878 ,  C07K2317/73 ,  Y02A50/463 ,  Y02A50/465 ,  Y02A50/475 ,  Y02A50/481

摘要： There is provided a polypeptide having a functional activity of IL-21 wherein the polypeptide has at least 80% identity to an IL-21 polypeptide comprising residues 41 (Gln) to 148 (Ile) of SEQ ID NO:2 or residues 32 (Gln) to 162 (Ser) of SEQ ID NO:2, for use in treating a viral infection.

摘要翻译： 提供了具有IL-21功能活性的多肽，其中多肽与SEQ ID NO：2的残基41（Gln）至148（Ile）或残基32（Gln）的IL-21多肽具有至少80％的同一性 ）至162（Ser）的SEQ ID NO：2，用于治疗病毒感染。

公开(公告)号：EP2368566A1

公开(公告)日：2011-09-28

申请号：EP11171346.7

申请日：2007-07-13

申请人： ZymoGenetics, Inc.

发明人： Sivakumar, Pallavur V. ,  Hausman, Diana F. ,  Hughes, Steven D. ,  Sievers, Eric ,  Miller, Dennis M.

IPC分类号： A61K38/20 ,  A61K31/4412 ,  A61K31/404 ,  A61P35/00

CPC分类号： A61K45/06 ,  A61K31/404 ,  A61K31/4412 ,  A61K38/20 ,  A61K2300/00

摘要： There is provided a composition comprising IL-21 polypeptide and a composition comprising a tyrosine kinase inhibitor, for use in treating cancer selected from renal cell carcinoma, metastatic melanoma, or hepatocellular carcinoma, wherein said use comprises co-administration of said compositions to a patient.

摘要翻译： 提供了包含IL-21多肽和包含酪氨酸激酶抑制剂的组合物的组合物，其用于治疗选自肾细胞癌，转移性黑素瘤或肝细胞癌的癌症，其中所述用途包括将所述组合物共同给予患者 。

公开(公告)号：EP2271675A4

公开(公告)日：2011-08-24

申请号：EP09731098

申请日：2009-04-07

申请人： ZYMOGENETICS INC

发明人： BISHOP PAUL D ,  POWNDER TRACEY A ,  SHEPPARD PAUL O ,  STENLAND CHRISTOPHER J

IPC分类号： C07K17/00

CPC分类号： C12N9/6418 ,  C07K2319/50

公开(公告)号：EP1828239B1

公开(公告)日：2011-08-24

申请号：EP05853969.3

申请日：2005-12-12

申请人： ZymoGenetics, Inc.

发明人： REARDON, Brian J. ,  JULIEN, Susan D. ,  CHAN, Chung-leung ,  LIU, Hong, Y.

IPC分类号： C07K14/50

CPC分类号： C07K14/501 ,  C07K14/50

摘要： The expression vectors and methods using an E. coli expression system for the large scale production of FGF18 are described. The vectors utilize the FGF18 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Using the expression vectors, the FGF18 gene was produced in E. coli to a level of greater than 1 g/L in fed batch fermentation. Also included are OmpT deficient E. coli strains, as well as OmpT and fhuA negative strains transformed with an FGF18 expression vector.

公开(公告)号：EP2289525A1

公开(公告)日：2011-03-02

申请号：EP10171625.6

申请日：2003-06-06

申请人： ZymoGenetics, Inc.

发明人： Nelson, Andrew J. ,  Hughes, Steven D. ,  Holly, Richard D. ,  Kindsvogel, Wayne, R.

IPC分类号： A61K35/14 ,  A61K35/28 ,  C12N5/00 ,  A61P35/00

CPC分类号： C07K14/54 ,  A61K38/193 ,  A61K38/20 ,  A61K38/2013 ,  A61K38/2026 ,  A61K38/2086 ,  A61K45/06 ,  C07K16/2878 ,  C07K2317/73 ,  Y02A50/463 ,  Y02A50/465 ,  Y02A50/475 ,  Y02A50/481

摘要： There is provided an in vitro method for expansion of hematopoietic cells and hematopoietic cell progenitors comprising: culturing bone marrow or peripheral blood cells with a composition comprising an amount of IL-21 sufficient to produce an increase in the number of lymphoid cells in the bone marrow or peripheral blood cells as compared to bone marrow or peripheral blood cells cultured in the absence of IL-21. There are also provided anti-cancer effector cells for use in the treatment of cancer in a patient by adoptive immunotherapy, wherein said anti-cancer effector cells have been obtained from the patient, and wherein the use comprises an initial ex vivo step of expanding the anti-cancer effector cells in culture in the presence of IL-21.

摘要翻译： 有体外方法提供了一种用于造血细胞和造血细胞祖细胞，其包括扩展：培养骨髓或外周血细胞用包含的量的组合物IL-21足以产生增加的淋巴样细胞的数目在骨髓 或外周血细胞相比，骨髓或在不存在IL-21的培养外周血细胞 所以设置有抗癌效应细胞用于在通过过继免疫治疗患者的癌症中的用途，worin所述抗癌效应细胞havebeen从患者获得，和worin扩大的初始体外步骤的所述用途包括 抗癌效应细胞在培养物中的IL-21的存在

公开(公告)号：EP2283355A2

公开(公告)日：2011-02-16

申请号：EP09735473.2

申请日：2009-04-22

申请人： Zymogenetics, Inc. ,  University of Washington

发明人： GROSS, Jane, A. ,  ELKON, Keith, B. ,  DILLON, Stacey, R.

IPC分类号： G01N33/50

CPC分类号： C07K16/24 ,  C07K14/70578 ,  G01N33/5091 ,  G01N33/564 ,  G01N2333/70575 ,  G01N2800/042 ,  G01N2800/065 ,  G01N2800/101 ,  G01N2800/102 ,  G01N2800/104 ,  G01N2800/24 ,  G01N2800/285 ,  G01N2800/347

摘要： The present invention provides a method of measuring the levels of BCMA in a biological sample, specifically upon the B cell surface. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as SLE, and for methods for treating an individual clinically diagnosed with an autoimmune disease. This diagnostic test serves to predict a patient's likelihood to respond to a specific drug treatment, in particular treatment with BLyS antagonists, either singly or in combination with other immune suppressive drugs